Current strategies to target p53 in cancer
- 1 September 2010
- journal article
- review article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 80 (5), 724-730
- https://doi.org/10.1016/j.bcp.2010.04.031
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced SarcomasPublished by Springer Science and Business Media LLC ,2009
- Therapeutic prospects for p73 and p63: Rising from the shadow of p53Drug Resistance Updates, 2008
- p53 Activation: A Case against SirCancer Cell, 2008
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 ActivatorCancer Cell, 2008
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenograftsProceedings of the National Academy of Sciences of the United States of America, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002